Categories Earnings, Retail

Coca-Cola brews something new with Costa

The Coca-Cola Company (KO) agreed to acquire Costa, a coffee shop chain owned by UK-based Whitbread Plc, for $5.1 billion. Costa, which is one of Starbucks’ chief rivals, has a presence in more than 30 countries and achieved $1.6 billion in revenues during its recently-ended fiscal year.

The deal, which is expected to close in the first half of 2019, will give Coca-Cola a sizeable international store presence through Costa’s 4,000 stores. Whitbread had plans to spin off Costa and Coca-Cola’s price is said to offer more value than what the British company would have gained if Costa was turned into a standalone entity.

Coca-Cola and Costa both have an extensive presence across various markets in their respective fields, and this deal is expected to benefit both companies regarding expansion and product diversification. The acquisition is anticipated to open up new growth and expansion opportunities for Coca-Cola across Europe, Asia, and the Middle East. Costa has a notable presence in China alongside Starbucks, which will now probably face tougher competition as a result of this combination.

The acquisition is anticipated to open up new growth and expansion opportunities for Coca-Cola across Europe, Asia, and the Middle East

As customer preferences change, prominent Cola companies are modifying their strategy and shifting to various other products aside from sugary drinks, as can be seen from Pepsi’s (PEP) recent acquisition of sparkling water company SodaStream International (SODA) for $3.2 billion.

Coffee is one such product which is seeing good sales, and the Costa deal provides growth opportunities to Coca-Cola, which is relatively new to coffee. Recently, Nestle and Starbucks (SBUX) entered into a distribution partnership for over $7 billion.

Whitbread shares rose close to 20% during early trading hours in London after news of the deal broke.

Coca-Cola acquisitions

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top